Discussion: This result is consistent with a previous study demonstrating that the HBx with A1762T/G1764A (K130M/V131I) mutation (the same as M1-HBx in our study) had a stronger tumorigenic effect than its WT counterpart in a SB mouse model.
rt269I Type of Hepatitis B Virus (HBV) Polymerase versus rt269L Is More Prone to Mutations within HBV Genome in Chronic Patients Infected with Genotype C2: Evidence from Analysis of Full HBV Genotype C2 Genome.
Abstract: We also found that there are a total of 19 signature single nucleotide polymorphisms (SNPs), of which 2 and 17 nonsynonymous mutation types were specific to rt269L and rt269I, respectively: Of these, most are HBeAg negative infections (preC-W28*, X-V5M and V131I), lowered HBV DNA or virion production (C-I97F/L, rtM204I/V) or preexisting nucleot(s)ide analog resistance (NAr) (rtN139K/H, rtM204I/V and
Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants.
Abstract: IMPLICATIONS: Our findings suggested that HBx-K130M/V131I-mutant variant promoted HCC progression by activating AKT/FOXO1 pathway and inducing stronger inflammation in liver via AA metabolism.
Abstract: Taken together, the increased rate of HCC observed in chronic hepatitis B patients with K130M/V131I-mutated X protein, may be due to changes in AA metabolism and AKT/FOXO1 signaling.
Abstract: To compare the potential tumorigenic effects of K130M/V131I (Mut) and wild-type (WT) HBx on PMID: 31341154
2019
The Kobe journal of medical sciences
Abstract: In addition, the double mutation K130M/V131I and the triple mutation N88V/K130M/V131I were associated with a 2.5 times higher risk of advanced liver disease.
Association between host TNF-alpha, TGF-beta1, p53 polymorphisms, HBV X gene mutation, HBV viral load and the progression of HBV-associated chronic liver disease in Indonesian patients.
Abstract: Multinomial regression analysis revealed that the K130M/V131I mutations were correlated with CLD progression (OR, 7.629; 95% CI, 1.578-36.884).
Abstract: Significant differences in viral load were found in HBV-infected patients who had X gene mutations, such as R87W/G, I127L/T/N/S and K130M/V131I mutations (P<0.05).
Abstract: The presence of K130M and V131I mutations may be predictive for the progression of HBV-associated CLD in Indonesia.
Result: Multinomial regression analysis confirmed that K130M/V131I mutati
Hepatitis B virus X protein: The X factor in chronic hepatitis B virus disease progression.
PMID: 32003338
2019
Indian journal of medical microbiology
Abstract: The frequency of aminoacid substitution in proapoptotic domain was higher in HBeAg negative participants including I127V (34%), K130M (34%), V131I (40%).
Abstract: The frequency of double mutation (K130M+V131I) and triple mutation (I127V+K130M+V131I) were found to be higher (32% and 36%) in HBeAg negative participants.
The Correlation Between Hepatitis B Virus Precore/Core Mutations and the Progression of Severe Liver Disease.
PMID: 30406036
2018
Frontiers in cellular and infection microbiology
Introduction: Mutations within the X gene, including V5M, I127T, K130M, and V131I/L, are risk factors for HCC and may promote the progression of liver degradation (Kim et al.,).
HBx-K130M/V131I Promotes Liver Cancer in Transgenic Mice via AKT/FOXO1 Signaling Pathway and Arachidonic Acid Metabolism.
Abstract: Hepatitis B virus (HBV) genomic mutations A1762T, G1764A and AG1762/1764TA cause production of HBV X protein (HBx) mutants, namely K130M, V131I and KV130/131MI.
Hepatitis B virus (HBV) X gene mutations and their association with liver disease progression in HBV-infected patients.
Abstract: I127T, V131I, and F132Y/I/R mutations showed a significant increasing trend associated with the disease progression to HCC.
Abstract: One double mutation (K130M+V131I) and two triple mutations (I127T+K130M+V131L and K130M+V131I+F132Y) were observed, with significant rising prevalence through progressive clinical phases of liver disease to HCC.
HBV mutation literature information.
PMID: 
2022
Frontiers in oncology
Browser Board
Co-occurred Entities
Filtrator
ViMRT